Analytical Data
-
Gene name
gABRe
- Application
-
Alternative Names
GABA(A) receptor subunit epsilon
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P78334
-
Expression Region
Pro23~Ile187
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of gABRe recombinant protein has gained significance in recent years due to its potential role in various biological processes and its implications in therapeutic applications. gABRe, a member of the GABA receptor family, is involved in mediating inhibitory neurotransmission in the central nervous system. Research has shown that alterations in the function or expression of gABRe can be linked to various neurological disorders, including epilepsy, anxiety, and depression. As a result, understanding the structure and function of gABRe at the molecular level is crucial for the development of novel pharmacological agents aimed at modulating its activity. The use of recombinant DNA technology allows for the expression of gABRe proteins in host systems, facilitating the study of its properties, interactions, and mechanisms of action. By producing gABRe in a controlled laboratory setting, researchers can conduct detailed experiments to investigate its binding affinities with ligands, the effects of point mutations, and its signaling pathways. This research not only enhances our understanding of gABRe's role in the nervous system but also opens avenues for targeting these receptors in drug design, which could lead to improved treatments for mental health disorders. Overall, the exploration of gABRe recombinant protein represents a significant frontier in neurobiological research, with the potential to translate into clinical innovations aimed at ameliorating human health issues related to neurotransmission dysregulation.
